TheraCea stands as an active participant in the transformative Back-to-Work Small Business Hiring and Retention Program. This program, meticulously crafted to bolster the growth of small, community-rooted enterprises, holds a key role in our operational strategy. By aligning with this initiative, we are empowered to effectively recruit and maintain a talented workforce, further solidifying our commitment to both our business growth and the local economy. With the program offering financial support of up to $10,000, encompassing hiring and signing bonuses, relocation incentives for new employees, and bonuses aimed at retaining our valuable team, TheraCea is poised to thrive in the dynamic landscape of modern business.
UArizona bioscience startup selected for Flinn Foundation program
TheraCea obtains recognition from Flinn Foundation.
“Tucson-based TheraCea Pharma addresses the greatest challenge in the emerging $145 billion cancer immunotherapy market by providing clinical diagnostic products for patient selection and therapy guidance. TheraCea detects immunotherapy biomarkers using PET imaging. The company has developed a set of diagnostic agents that allow oncologists and pharmaceutical companies to select the right segment of patients who will be responsive to specific immunotherapy drugs.” - Flinn Foundation
TheraCea Awarded Through NIH's TABA Assessment
We are thrilled to announce that our pioneering efforts in the field of radiopharmaceutical kits for immunotherapy have been recognized with the prestigious NIH TABA (Technology Assessment for Biomedical Applications) award. This accolade underscores our commitment to advancing medical science and underscores our dedication to developing cutting-edge solutions that enhance immunotherapy outcomes. The NIH TABA assessment award serves as a testament to our team's unwavering dedication, innovation, and impact in revolutionizing radiopharmaceutical research and its application in the realm of immunotherapy. We remain steadfast in our mission to shape the future of healthcare through groundbreaking advancements.
TheraCea Participates in Destination Startup Showcase
TheraCea marked a significant milestone by participating in the esteemed Destination Startup® 2022 Showcase. This event, an embodiment of collaboration between premier research universities and federal laboratories across the Intermountain West region, serves as a vanguard for our innovation ecosystem. Since its inception in 2019, Destination Startup® has attracted over 600 investors, prominent business figures, and thought leaders from across the nation, fostering invaluable connections. Notably, companies showcased within this platform have collectively secured a remarkable $110 million in venture capital, angel investments, and grant funding. By being part of Destination Startup®, TheraCea not only demonstrates its pioneering spirit but also contributes to the potent synergy between groundbreaking research and impactful business ventures, propelling our mission to reshape the landscape of radiopharmaceuticals and immunotherapy.
TheraCea Receives FAST Award
TheraCea is proud to announce its achievement of the esteemed FAST Award, an accolade conferred by the Small Business Administration's Federal and State Technology (FAST) Partnership Program. This recognition underscores our unwavering commitment to innovation and technology-driven progress within the small business landscape. Collaborating closely with the Arizona Commerce Authority and the Small Business Administration, our participation in the FAST program has been instrumental in propelling our entrepreneurial journey. By providing crucial funding, invaluable resources, comprehensive training, and vital networking opportunities, Arizona's FAST program has empowered TheraCea to excel in crafting compelling Small Business Innovation Research (SBIR) proposals. This accolade translates into enhanced competitiveness in securing federal funding for innovation, research, and development initiatives, further cementing TheraCea's position as a frontrunner in the radiopharmaceutical and immunotherapy realm.